Earlier this month, CMS proposed a policy that would severely limit Medicare beneficiaries being evaluated for dementia from an innovative new technology capable of providing a more precise diagnosis as to the form of dementia and enabling patients to receive timely and effective treatments and care. USAgainstAlzheimer’s has been highly critical of this proposal and has marshaled our resources to change this policy. Comments from USAgainstAlzheimer’s as well as our affiliate network ResearchersAgainstAlzheimer’s were submitted on Friday to CMS.
Click here to view USAgainstAlzheimer's comments.
Click here to view ResearchersAgainstAlzheimer's comments.